C Liedtke

Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer

C Liedtke, Kristine Broglio, Stacey Moulder et al. · Annals of Oncology · 2009 · 299 citations · Full text

Medicine, Biostatistics, Oncology +13

De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR− phase II trial: efficacy, safety, and predictive markers for 12 weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab ± weekly paclitaxel

Ulrike Nitz, Oleg Gluz, Matthias Christgen et al. · Annals of Oncology · 2017 · 172 citations

Medicine, Oncology, Pharmacology +17

Expression of secreted protein acidic and rich in cysteine (SPARC) in breast cancer and response to neoadjuvant chemotherapy

Judith Lindner, Sibylle Loibl, Carsten Denkert et al. · Annals of Oncology · 2014 · 96 citations · Full text

Medicine, Cancer Biology, Oncology +14

Squalene epoxidase, located on chromosome 8q24.1, is upregulated in 8q+ breast cancer and indicates poor clinical outcome in stage I and II disease

Mike W. Helms, Dirk Kemming, Heike Pospisil et al. · British Journal of Cancer · 2008 · 61 citations · Full text

Medicine, Genetics, Oncology +17

Predictive value of HER2 serum levels in patients treated with lapatinib or trastuzumab – a translational project in the neoadjuvant GeparQuinto trial

Isabell Witzel, Sibylle Loibl, Gϋnter von Minckwitz et al. · British Journal of Cancer · 2012 · 32 citations · Full text

Medicine, Oncology, Pharmacology +16